Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.57B | $3.61B | $5.07 |
| 2024 | $23.88B | $3.90B | $5.33 |
| 2023 | $23.89B | $4.76B | $6.44 |
| 2022 | $26.64B | $7.21B | $9.80 |
| 2021 | $29.45B | $6.43B | $8.77 |
Social Signal Score
Earnings
Tue, Oct 20(in 2 months)
Consensus estimate $1.92 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$1.94 vs $1.85beat
- Tue, Apr 21$2.06 vs $1.94beat
- Wed, Jan 28$2.23 vs $2.16beat
- Tue, Oct 21$1.89 vs $1.72beat
- Tue, Jul 22$1.80 vs $1.64beat
- Tue, Apr 22$1.88 vs $1.63beat
Estimates and results for DHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DHR's reported EPS growth of -12.8% a year over 4 years.
- EPS in 5 years
- $2.58
- Implied price
- $115.93
- Return from $202.45
- -10.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $57.64 — -71.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 31 | 38 | 45 | 52 | 59 |
|---|---|---|---|---|---|
| -22.8% | -26.5% | -23.4% | -20.8% | -18.5% | -16.4% |
| -17.8% | -21.7% | -18.5% | -15.7% | -13.2% | -11.0% |
| -12.8% | -17.0% | -13.5% | -10.6% | -7.9% | -5.6% |
| -7.8% | -12.2% | -8.6% | -5.4% | -2.6% | -0.2% |
| -2.8% | -7.5% | -3.6% | -0.3% | 2.6% | 5.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsseekingalpha.com·1d ago·Positive
Danaher: 2027 Growth Reacceleration Should Drive Upside Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.
View source ↗